Current Report Filing (8-k)
August 13 2018 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 10, 2018
Imprimis
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12264 El Camino Real, Suite 350
San
Diego, California
|
|
92130
|
(Address of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(858) 704-4040
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events.
On
August 10, 2018, Eton Pharmaceuticals, Inc. (“Eton”) filed a registration statement on Form S-1 with the United States
Securities and Exchange Commission related to an initial public offering of Eton’s common stock in an underwritten offering.
The registration statement contains, among other things, a description of Eton’s business, financial statements and plans.
Imprimis
Pharmaceuticals, Inc. owns three million five hundred thousand (3,500,000) shares of Eton common stock.
This
Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Imprimis
Pharmaceuticals, Inc.
|
|
|
Date:
August 13, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew
R. Boll
|
|
Title:
|
Chief
Financial Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Apr 2024 to May 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2023 to May 2024